Supplementary Figure S7: The expression levels of SCRN1 are anti-correlated with the IC 50 value to erlotinib in cancer cell lines. The relationship between SCRN1 expression level and response to erlotinib were examined by comparing log10 half maximum inhibitory concentration (IC 50 ) values for erlotinib in cell lines between high SCRN1-expressing (n = 37) and low expressing (n = 54) cell lines (data obtained from CCLE). We downloaded CCLE anti-cancer drug sensitivity and gene expression data for human tumor cell lines (http://www.broadinstitute.org/ccle). The downloaded gene expression profile was pre-processed by z-score transformation across samples. To measure the association between the gene expression level of SCRN1 and response to erlotinib, IC 50 values for erlotinib in cell lines were compared between two groups, high SCRN1-expressing and low expressing cell lines (using a cutoff value = 0.5). The significant difference was observed between two groups (p = 0.05), which were compared using the Student's t-test. Imielinski et al, 2012. Strong tendency towards mutual exclusivity ( 0 < Odds ratio < 0.1 ); Some tendency towards mutual exclusivity ( 0.1 < Odds ratio < 0.5 ); No association ( 0.5 < Odds ratio < 2 ); Tendency toward co-occurrence ( 2 < Odds ratio < 10 ); Strong tendency towards co-occurrence ( Odds ratio > 10 ). * Clinical characteristics and expression of the indicated biomarkers in the 11 EGFR mutant NSCLC specimens obtained from patients upon acquired resistance to treatment to gefitinib. M, male; F, female; PFS, progression free survival, interval between the beginning of EGFR-TKI and the progression time; 0, never; 1, previous; 2, current smoking; N/A, not enough tissue available for analysis.
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